来源：新浪证券-红岸工作室 9月30日，君实生物涨0.90%，成交额3.57亿元。两融数据显示，当日君实生物获融资买入额3763.25万 元，融资偿还5328.34万元，融资净买入-1565.09万元。截至9月30日，君实生物融资融券余额合计13.89 亿元。 融资方面，君实生物当日融资买入3763.25万元。当前融资余额13.83亿元，占流通市值的4.35%，融资 余额超过近一年90%分位水平，处于高位。 机构持仓方面，截止2025年6月30日，君实生物十大流通股东中，华夏上证科创板50成份ETF （588000）位居第六大流通股东，持股2971.67万股，相比上期减少53.67万股。易方达上证科创板 50ETF（588080）位居第七大流通股东，持股2221.32万股，相比上期增加63.00万股。香港中央结算有 限公司位居第十大流通股东，持股1312.91万股，相比上期减少186.65万股。 资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 ...

资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为：药品销售90.67%，技术许可及特许权使用收入8.74%，技术服务及其他 0.59%。 来源：新浪证券-红岸工作室 10月9日，君实生物盘中下跌2.03%，截至10:03，报40.62元/股，成交1.93亿元，换手率0.61%，总市值 417.04亿元。 资金流向方面，主力资金净流出3038.12万元，特大单买入1470.52万元，占比7.62%，卖出3328.90万 元，占比17.25%；大单买入5172.48万元，占比26.81%，卖出6352.22万元，占比32.92%。 君实生物今年以来股价涨48.63%，近5个交易日跌2.52%，近20日跌12.40%，近60日涨7.09%。 君实生物所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：生物医药、创新 药 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 FF301 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 260,295,700 | | 0 | | 260,295,700 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 260,295,700 | | 0 | | 260,295,700 | 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [5]. Core Insights - The company reported a revenue of 1.168 billion yuan for H1 2025, representing a year-on-year growth of 48.64%. The net loss was 413 million yuan, a reduction in loss of 36.01% compared to the previous year [1]. - The sales revenue of the company's core product, Tislelizumab, in the domestic market reached approximately 954 million yuan in H1 2025, showing a year-on-year increase of about 42%. The product has received approval for 12 indications, with four new indications added to the medical insurance directory in 2025 [2]. - The PD-1/VEGF dual antibody, JS207, is currently in Phase II clinical trials, demonstrating strong anti-tumor activity in preclinical studies. It is being explored in various tumor types in combination with other therapies [3]. - The company has a rich pipeline of oncology drugs, with the anti-BTLA monoclonal antibody, Tifcemalimab (JS004), currently in Phase III clinical trials for LS-SCLC, having enrolled nearly 400 patients [4]. Financial Summary - The company's revenue projections for 2025 and 2026 have been revised down to 2.584 billion yuan and 3.441 billion yuan, respectively. The expected net loss for 2025 is adjusted to 675 million yuan [5]. - The company’s total market capitalization is approximately 31.77 billion yuan, with a total share capital of 766.39 million shares [6]. - The earnings per share (EPS) is projected to improve from -2.32 yuan in 2023 to 0.18 yuan in 2027, indicating a potential turnaround in profitability [9].

FF301 截至月份: 2025年9月30日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 260,295,700 | RMB | | 1 | RMB | | 260,295,700 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 260,295,700 | RMB | | 1 | RMB | | 260,295,700 | 第 2 ...

Group 1 - Pharmaceutical stocks are experiencing a strong rally, with notable increases in share prices for companies such as Clover Biopharmaceuticals (up 20.26%), Genscript Biotech (up 15.05%), and others [1] - On September 26, former President Trump announced a 100% tariff on any brand or patented pharmaceutical products starting October 1, 2025, unless companies establish manufacturing facilities in the U.S. [1] - Southwest Securities predicts uncertainty regarding the implementation of this executive order, suggesting that Chinese innovative drug companies heavily reliant on the U.S. market may face short-term pressure [1] - China’s innovative drug companies that engage in business development (BD) overseas are expected to be less affected, particularly those involved in license-out agreements, which are essentially intellectual property transactions [1] - China Post Securities believes the actual impact of the tariffs will be minimal, viewing the current price drop as a good opportunity to increase holdings in innovative drugs [1] Group 2 - From the perspective of catalysts in the innovative drug sector, October will see significant industry conferences such as ESMO (October 17-21), followed by ASH and the San Antonio Breast Cancer Symposium in December [2] - There has been ongoing progress in outbound licensing transactions this year, with several significant deals already completed, indicating potential opportunities for high-quality domestic innovative drugs to enter international markets [2] - The fourth quarter is expected to bring domestic policy implementations, including adjustments to the medical insurance catalog [2]

Core Insights - The latest shareholder equity disclosures for several companies were made on October 1, 2025, including Longji Group, Minth Group, Kingboard Laminates, Junshi Biosciences, and Bonny Holdings [1] Group 1: Longji Group (00255) - Shareholder Shao Yulong increased his holdings from 407 million shares to 414 million shares, raising his ownership percentage from 64.49% to 65.52% [2] - Shareholder Shao Tielong also increased his holdings from 407 million shares to 414 million shares, with the same ownership percentage change as Shao Yulong [2] Group 2: Minth Group (00425) - Shareholder Wei Qinglian maintained his holdings at 451 million shares, with a slight increase in ownership percentage from 38.34% to 38.35% [2] Group 3: Kingboard Laminates (01888) - Shareholder Ye Shukun reduced his holdings from 1.35 million shares to 1.15 million shares, resulting in a decrease in ownership percentage from 0.04% to 0.03% [2] Group 4: Junshi Biosciences (01877) - Shareholder Li Xin significantly increased his holdings from 82,900 shares to 1.2829 million shares, raising his ownership percentage from 0.04% to 0.49% [2] Group 5: Bonny Holdings (01906) - Hong Kong Jun He Limited completely divested from Bonny Holdings, reducing holdings from 550 million shares to 0 shares, resulting in a drop in ownership percentage from 37.39% to 0% [2]

Core Insights - Junshi Biosciences experienced a slight increase in stock price by 0.22% on September 29, with a trading volume of 531 million yuan [1] - The company reported a net financing outflow of 599.84 million yuan on the same day, indicating a higher level of financing activity compared to the past year [1][2] - As of June 30, 2025, Junshi Biosciences achieved a revenue of 1.168 billion yuan, marking a year-on-year growth of 48.64% [2] Financing and Margin Trading - On September 29, Junshi Biosciences had a financing buy-in amount of 44.49 million yuan, with a total financing balance of 13.99 billion yuan, representing 4.44% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of investor interest [1] - The company also had a margin trading balance of 599.84 million yuan, which is above the 60th percentile of the past year [1] Shareholder Structure - As of June 30, 2025, the number of shareholders for Junshi Biosciences increased to 31,200, a rise of 5.88% from the previous period [2] - The average number of circulating shares per shareholder decreased by 5.56% to 24,543 shares [2] - Major institutional shareholders include Huaxia SSE STAR 50 ETF and E Fund SSE STAR 50 ETF, with varying changes in their holdings [3]

Group 1 - The company has elected Ms. Li Xin as the employee representative director for the fourth board of directors, with her term starting from the approval date of the election and lasting until the end of the board's term [1][2][4] - Ms. Li Xin was previously a non-employee representative director and her election ensures that the number of directors who are also senior management or employee representatives does not exceed half of the total number of directors [2][5] Group 2 - The company held its first extraordinary general meeting of shareholders on September 29, 2025, where all proposed resolutions were approved without any being rejected [8][10] - The meeting was conducted in compliance with the Company Law and the company's articles of association, with all 14 current directors and 3 supervisors present [9][22] Group 3 - The company approved the adjustment of its 2025 A-share stock option incentive plan, reducing the number of initial grant recipients from 251 to 235 and the total number of stock options from 25.36 million to 25.15 million [23][39] - The stock options will be granted at a price of 46.67 yuan per share, with the total number of options granted representing approximately 2.45% of the company's total share capital [35][42] Group 4 - The company conducted a self-examination regarding insider trading related to the stock option incentive plan, confirming that no insider information was leaked and that all trading activities were based on public market information [18][19][58] - The company has established a comprehensive approval process for the stock option incentive plan, ensuring compliance with relevant laws and regulations [61][62]

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 調整激勵對象名單及擬授予數量 及根據2025年A股股票期權計劃 向激勵對象首次授予A股股票期權 茲提述上海君實生物醫藥科技股份有限公司（「本公司」）日期為2025年9月2日的 公告及日期為2025年9月5日的通函（「該通函」），內容有關（其中包括）本公司 2025年A股股票期權激勵計劃及建議向熊先生授予。除非文義另有所指，否則本 公告所用詞彙與該通函所界定者具有相同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 調整首次授予A股股票期權之激勵對象名單及擬授予數量 由於16名激勵對象因離職失去激勵資格或因其他原因自願放棄激勵資格，董事會 及薪酬與考核委員會已決議根據股東於臨時股東大會的授權，對2025年A股股票 期權激勵計劃首次授予激勵對象名單、授予數量進行了調整。本 ...